{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:33:01Z","timestamp":1791505981632,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T00:00:00Z","timestamp":1558742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T00:00:00Z","timestamp":1558742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00415-019-09395-w","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T14:03:47Z","timestamp":1558793027000},"page":"3489-3498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing\u2013remitting multiple sclerosis: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"267","author":[{"given":"Huihui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengli","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,25]]},"reference":[{"issue":"9648","key":"9395_CR1","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A (2008) Multiple sclerosis. Lancet 372(9648):1502\u20131517. https:\/\/doi.org\/10.1016\/S0140-6736(08)61620-7","journal-title":"Lancet"},{"issue":"11","key":"9395_CR2","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1212\/WNL.0000000000000768","volume":"83","author":"P Browne","year":"2014","unstructured":"Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ (2014) Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 83(11):1022\u20131024. https:\/\/doi.org\/10.1212\/WNL.0000000000000768","journal-title":"Neurology"},{"issue":"10130","key":"9395_CR3","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O (2018) Multiple sclerosis. Lancet 391(10130):1622\u20131636. https:\/\/doi.org\/10.1016\/S0140-6736(18)30481-1","journal-title":"Lancet"},{"issue":"3","key":"9395_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1212\/WNL.0b013e318207b060","volume":"76","author":"MJ Chao","year":"2011","unstructured":"Chao MJ, Ramagopalan SV, Herrera BM, Orton SM, Handunnetthi L, Lincoln MR, Dyment DA, Sadovnick AD, Ebers GC (2011) MHC transmission: insights into gender bias in MS susceptibility. Neurology 76(3):242\u2013246. https:\/\/doi.org\/10.1212\/WNL.0b013e318207b060","journal-title":"Neurology"},{"issue":"2","key":"9395_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. N Engl J Med 378(2):169\u2013180. https:\/\/doi.org\/10.1056\/NEJMra1401483","journal-title":"N Engl J Med"},{"issue":"4","key":"9395_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.clinthera.2015.03.001","volume":"37","author":"C English","year":"2015","unstructured":"English C, Aloi JJ (2015) New FDA-approved disease-modifying therapies for multiple sclerosis. Clin Ther 37(4):691\u2013715. https:\/\/doi.org\/10.1016\/j.clinthera.2015.03.001","journal-title":"Clin Ther"},{"issue":"10076","key":"9395_CR7","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","volume":"389","author":"G Comi","year":"2017","unstructured":"Comi G, Radaelli M, Soelberg S\u00f8rensen P (2017) Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet 389(10076):1347\u20131356. https:\/\/doi.org\/10.1016\/S0140-6736(16)32388-1","journal-title":"Lancet"},{"issue":"2","key":"9395_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F (2018) ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 24(2):96\u2013120. https:\/\/doi.org\/10.1177\/1352458517751049","journal-title":"Mult Scler"},{"issue":"2","key":"9395_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/ene.13536","volume":"25","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F (2018) ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol 25(2):215\u2013237. https:\/\/doi.org\/10.1111\/ene.13536","journal-title":"Eur J Neurol"},{"issue":"17","key":"9395_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree B, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius T, Merillat SA, Pringsheim T (2018) Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology. Neurology 90(17):777\u2013788. https:\/\/doi.org\/10.1212\/WNL.0000000000005347","journal-title":"Neurology"},{"issue":"17","key":"9395_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1212\/WNL.0000000000005345","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree B, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius T, Merillat SA, Pringsheim T (2018) Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology. Neurology 90(17):789\u2013800. https:\/\/doi.org\/10.1212\/WNL.0000000000005345","journal-title":"Neurology"},{"issue":"4","key":"9395_CR12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/WNL.46.4.907","volume":"46","author":"FD Lublin","year":"1996","unstructured":"Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey national multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology 46(4):907\u2013911","journal-title":"Neurology"},{"issue":"4","key":"9395_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2174\/1567202043362180","volume":"1","author":"A Mouzaki","year":"2004","unstructured":"Mouzaki A, Tselios T, Papathanassopoulos P, Matsoukas I, Chatzantoni K (2004) Immunotherapy for multiple sclerosis: basic insights for new clinical strategies. Curr Neurovasc Res 1(4):325\u2013340","journal-title":"Curr Neurovasc Res"},{"issue":"3","key":"9395_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ana.410130302","volume":"13","author":"CM Poser","year":"1983","unstructured":"Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227\u2013231. https:\/\/doi.org\/10.1002\/ana.410130302","journal-title":"Ann Neurol"},{"issue":"1","key":"9395_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"WI McDonald","year":"2001","unstructured":"McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121\u2013127","journal-title":"Ann Neurol"},{"issue":"6","key":"9395_CR16","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O\u2019Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d. Ann Neurol 58(6):840\u2013846. https:\/\/doi.org\/10.1002\/ana.20703","journal-title":"Ann Neurol"},{"issue":"2","key":"9395_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O\u2019Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292\u2013302. https:\/\/doi.org\/10.1002\/ana.22366","journal-title":"Ann Neurol"},{"issue":"2","key":"9395_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintor\u00e9 M, Traboulsee AL, Trojano M, Uitdehaag B, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"issue":"11","key":"9395_CR19","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444\u20131452","journal-title":"Neurology"},{"issue":"4","key":"9395_CR20","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S1474-4422(11)70020-5","volume":"10","author":"AJ Coles","year":"2011","unstructured":"Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA (2011) Alemtuzumab versus interferon \u03b2-1a in early relapsing-remitting multiple sclerosis: post hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 10(4):338\u2013348. https:\/\/doi.org\/10.1016\/S1474-4422(11)70020-5","journal-title":"Lancet Neurol"},{"issue":"6","key":"9395_CR21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40263-018-0530-8","volume":"32","author":"B Uitdehaag","year":"2018","unstructured":"Uitdehaag B (2018) Disability outcome measures in phase III clinical trials in multiple sclerosis. CNS Drugs 32(6):543\u2013558. https:\/\/doi.org\/10.1007\/s40263-018-0530-8","journal-title":"CNS Drugs"},{"issue":"5","key":"9395_CR22","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/jim-2016-000339","volume":"65","author":"DL Vargas","year":"2017","unstructured":"Vargas DL, Tyor WR (2017) Update on disease-modifying therapies for multiple sclerosis. J Investig Med 65(5):883\u2013891. https:\/\/doi.org\/10.1136\/jim-2016-000339","journal-title":"J Investig Med"},{"issue":"4","key":"9395_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","volume":"15","author":"N Scolding","year":"2015","unstructured":"Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A, Giovannoni G, Miller D, Rashid W, Schmierer K, Shehu A, Silber E, Young C, Zajicek J (2015) Association of British neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol 15(4):273\u2013279. https:\/\/doi.org\/10.1136\/practneurol-2015-001139","journal-title":"Pract Neurol"},{"issue":"12","key":"9395_CR24","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1001\/jamaneurol.2018.2689","volume":"75","author":"JR Berger","year":"2018","unstructured":"Berger JR, Markowitz C (2018) Deciding on the best multiple sclerosis therapy: tough choices. JAMA Neurol 75(12):1461\u20131462. https:\/\/doi.org\/10.1001\/jamaneurol.2018.2689","journal-title":"JAMA Neurol"},{"key":"9395_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011381.pub2","author":"I Tramacere","year":"2015","unstructured":"Tramacere I, Del Giovane C, Salanti G, D\u2019Amico R, Filippini G (2015) Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 18(9). https:\/\/doi.org\/10.1002\/14651858.CD011381.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"9395_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.msard.2016.06.001","volume":"9","author":"E Fogarty","year":"2016","unstructured":"Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M (2016) Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis. Mult Scler Relat Disord 9:23\u201330. https:\/\/doi.org\/10.1016\/j.msard.2016.06.001","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"9395_CR27","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40263-018-0541-5","volume":"32","author":"RC Lucchetta","year":"2018","unstructured":"Lucchetta RC, Tonin FS, Borba H, Leonart LP, Ferreira VL, Bonetti AF, Riveros BS, Becker J, Pontarolo R, Fernandez-Llim\u00f3s F, Wiens A (2018) Disease-modifying therapies for relapsing-remitting multiple sclerosis: a network meta-analysis. CNS Drugs 32(9):813\u2013826. https:\/\/doi.org\/10.1007\/s40263-018-0541-5","journal-title":"CNS Drugs"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09395-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09395-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09395-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T01:07:00Z","timestamp":1605748020000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09395-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,25]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9395"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09395-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,25]]},"assertion":[{"value":"30 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable. The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}